Literature DB >> 12871778

Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma.

Takashi Hirano1, Yunbo Gong, Koichi Yoshida, Yasufumi Kato, Koich Yashima, Masahiro Maeda, Ayako Nakagawa, Kaoru Fujioka, Tatsuo Ohira, Norihiko Ikeda, Yoshiro Ebihara, Gert Auer, Harubumi Kato.   

Abstract

TA02 (napsin A) associated with primary lung adenocarcinoma detected by the two-dimensional polyacrylamide gel electrophoresis (2-DE), has a molecular weight of 35.0 kDa and an isoelectric point 5.29. We developed a mouse monoclonal antibody against the N-terminal of the TA02 molecule (clone TMU-Ad02 (6A1)) and attempted to investigate its immunohistochemical reactivity for nodular lesions of the peripheral lung, and evaluate its usefulness for making a differential diagnosis between primary and metastatic lung adenocarcinomas. The TA02-immunohistochemical evaluation was carried out using surgically resected materials of 109 cases of lung cancer (76 cases of primary lung cancer and 33 cases of metastatic lung adenocarcinoma from other organs), five cases with mesothelioma, four cases with atypical adenomatous hyperplasia (AAH) and five cases with tuberculoma of the lung. In 39 out of 43 (90.7%) primary lung adenocarcinomas, positive immunohistochemical reactivity with a granular cytoplasmic staining pattern was observed. Even though two out of seven (28.6%) large cell carcinomas showed positive results with a granular staining pattern, the immunohistochemical staining intensity was weak. The other cancerous lesions containing metastatic lung adenocarcinoma and mesothelioma were all completely negative. In comparison with the immunohistochemical reactivity of TA02 and SpA, TA02 was superior to SpA both in terms of positive rate and immunohistochemical intensity. We concluded that the evaluation of TA02 expression in lung tumorous lesions was very valuable for discriminating between primary and metastatic lung adenocarcinoma, and TA02 was superior to SpA as a discriminating marker.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871778     DOI: 10.1016/s0169-5002(03)00194-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.

Authors:  Wei Zhao; Hui Wang; Yan Peng; Bo Tian; Lei Peng; Da-Chuan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.

Authors:  Nehad M R Abd El-Maqsoud; Ehab Rifat Tawfiek; Ayman Abdelmeged; Mohamed Fathy Abdel Rahman; Alaa A E Moustafa
Journal:  Tumour Biol       Date:  2015-10-01

4.  Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma.

Authors:  Peng Zhang; Yi-Ping Han; Ling Huang; Qiang Li; DA-Lie Ma
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

5.  Long-term survival after incomplete resection of immunohistochemically diagnosed T0N1 lung cancer: report of a case.

Authors:  Yotaro Izumi; Makio Mukai; Koji Kikuchi; Koichi Kobayashi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Authors:  Yoriko Yamashita; Tetsuro Nagasaka; Aya Naiki-Ito; Shinya Sato; Shugo Suzuki; Shinya Toyokuni; Masafumi Ito; Satoru Takahashi
Journal:  Mod Pathol       Date:  2014-04-11       Impact factor: 7.842

7.  Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.

Authors:  Linshui Zhou; Xin Lv; Junchao Yang; Yuanhong Zhu; Zhen Wang; Tingzhen Xu
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

8.  Synchronous colorectal and lung cancer: report of three cases.

Authors:  Yi-Fan Peng; Jin Gu
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

9.  Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung.

Authors:  H Schultz; S Marwitz; B Baron-Lühr; G Zissel; C Kugler; K F Rabe; P Zabel; E Vollmer; J Gerdes; T Goldmann
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

10.  The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D.

Authors:  Takuya Samukawa; Tsutomu Hamada; Hirofumi Uto; Masakazu Yanagi; Go Tsukuya; Tsuyoshi Nosaki; Masahiro Maeda; Takashi Hirano; Hirohito Tsubouchi; Hiromasa Inoue
Journal:  BMC Pulm Med       Date:  2012-09-11       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.